Scott Gottlieb
InvestorSpecial Partner at New Enterprise Associates (NEA) · Independent Member of the Board of Directors at Pfizer Venture Investments · Board director at MedAvante
Chevy Chase, Maryland
Writes $2M – $50M checks · typically $25M
Find your path to Scott
574 people in our graph share verified history with Scott — schools, employers, funds. One of them is your warm intro.
About
Scott Gottlieb is a physician and policy expert who joined NEA's healthcare investment team as a Special Partner in 2019, having previously been a Venture Partner at the firm from 2007 to 2017. Between those roles he served as the 23rd Commissioner of the U.S. Food and Drug Administration (2017–2019), and earlier held positions as FDA Deputy Commissioner and Senior Adviser at the Centers for Medicare and Medicaid Services. He was a practicing hospitalist and Clinical Assistant Professor at NYU School of Medicine, is a graduate of Mount Sinai School of Medicine and Wesleyan University, and at NEA focuses on healthcare investing with an emphasis on biopharma and healthcare services.
Contact· self-published, not guessed
Invests in
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Beyond investing
- Education
- Studied at Wesleyan University (BA, economics) Studied at Icahn School of Medicine at Mount Sinai (MD)
- Boards
- Gottlieb was a member of the policy board of the Leukemia & Lymphoma Society.
- Communities
- Gottlieb is a contributor to CNBC and the CBS News program Face the Nation. Gottlieb served on the Federal Health Information Technology Policy Committee, which advises the U.S. Department of Health and Human Services.
- Awards
- Gottlieb is an elected member of the National Academy of Medicine.
- Family
- Gottlieb grew up in East Brunswick, New Jersey, the son of Stanley, a psychiatrist, and Marsha Gottlieb, a schoolteacher, and his family is Jewish.
From published sources — common ground for a warm intro.
Board director at MedAvante
Experience
- New Enterprise AssociatesPartnercurrent2007 — presentChevy Chase, MD
- American Enterprise InstituteSenior Fellowcurrent2003 — presentWashington D.C. Metro Area
- National Academy of MedicineElected Membercurrent2018 — presentWashington D.C. Metro Area
- PfizerIndependent Member of the Board of Directorscurrent2019 — presentBoston, MA
- UnitedHealth GroupIndependent Member of the Board of Directorscurrent2025 — presentMinnesota, United States
- IlluminaChairman of the Board of Directorscurrent2020 — presentSan Diego, California, United States
- Xaira TherapeuticsBoard Membercurrent2024 — presentSan Francisco, California, United States
- Comanche BiopharmaBoard Membercurrent2024 — presentBoston, Massachusetts, United States
- ResilienceBoard Membercurrent2020 — presentBoston, Massachusetts, United States
- AetionBoard Membercurrent2019 — presentNew York, United States
- Tempus AIIndependent Member of the Board of Directorscurrent2019 — presentChicago, Illinois, United States
- FDACommissioner2017 — 2019White Oak, MD
- U.S. Department of Health and Human Services (HHS)Member Federal Health IT Policy Committee2013 — 2017Washington, DC
- Society of Hospital MedicineMember of the Policy Board2011 — 2017
- Daiichi Sankyo, Inc.Independent Member of the Board of Directors2015 — 2017Livingston, NJ
- American Pathology PartnersIndependent Member of the Board of Directors2012 — 2017Denver, CO
- NYU Langone HealthClinical Assistant Professor2011 — 2017New York, NY
- GlaxoSmithKlineMember of the Product Investment Board2010 — 2017Greater Philadelphia Area
- Gradalis, Inc.Independent Member of the Board of Directors2015 — 2017Dallas, TX
- MedAvanteIndependent Member of the Board of Directors2007 — 2017Princeton, NJ
Skills & more
From Scott's professional profile.
Deals · 1
Tempus LabsBoard seat
via New Enterprise Associates (NEA) · filed Oct 2022 · $10M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
American Pathology PartnersBravo HealthDaiichi Sankyo Inc.Illumina, Inc.Kure Corp.Pfizer, IncTolero PharmaceuticalsUnitedHealth Group
Sources: curated public sources · SEC Form D filings.
Colleagues at New Enterprise Associates (NEA)
Frequently asked questions
- Who is Scott Gottlieb?
- Scott Gottlieb is a physician and policy expert who joined NEA's healthcare investment team as a Special Partner in 2019, having previously been a Venture Partner at the firm from 2007 to 2017. Between those roles he served as the 23rd Commissioner of the U.S. Food and Drug Administration (2017–2019), and earlier held positions as FDA Deputy Commissioner and Senior Adviser at the Centers for Medicare and Medicaid Services. He was a practicing hospitalist and Clinical Assistant Professor at NYU School of Medicine, is a graduate of Mount Sinai School of Medicine and Wesleyan University, and at NEA focuses on healthcare investing with an emphasis on biopharma and healthcare services.
- Where does Scott Gottlieb work?
- Scott Gottlieb is Special Partner at New Enterprise Associates (NEA) and Board director at MedAvante.
- What does Scott Gottlieb invest in?
- Scott Gottlieb invests in AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
- What check size does Scott Gottlieb write?
- Scott Gottlieb typically writes checks of $2M – $50M.
- What boards does Scott Gottlieb sit on?
- Scott Gottlieb holds tracked board seats at American Pathology Partners, Bravo Health, Daiichi Sankyo Inc., Illumina, Inc., Kure Corp., Pfizer, Inc, Tempus Labs, Tolero Pharmaceuticals, UnitedHealth Group.
- Where did Scott Gottlieb go to school?
- Scott Gottlieb studied at Icahn School of Medicine at Mount Sinai (Resident, Internal Medicine Residency Program); Icahn School of Medicine at Mount Sinai (Doctor of Medicine (MD), Medicine).
- What awards has Scott Gottlieb received?
- Gottlieb is an elected member of the National Academy of Medicine.
Same school
Also attended Icahn School of Medicine at Mount Sinai37
+ 31 more
Shared employers
Also worked at American Enterprise Institute14
+ 8 more
Also worked at National Academy of Medicine7
+ 1 more
Also worked at UnitedHealth Group152
+ 146 more
Also worked at Xaira Therapeutics7
+ 1 more




















































